JMP Securities Reiterated Loxo Oncology (NASDAQ:LOXO) As a Buy; They Now Have a Target Price per Share Of $215.0000

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

Investors sentiment increased to 1.74 in 2018 Q2. Its up 0.58, from 1.16 in 2018Q1. It improved, as 8 investors sold Loxo Oncology, Inc. shares while 57 reduced holdings. 58 funds opened positions while 55 raised stakes. 28.62 million shares or 4.87% less from 30.09 million shares in 2018Q1 were reported.

Blair William & Il stated it has 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Advisory Rech holds 9,805 shares. Opus Point Mngmt Limited Liability Corporation stated it has 6,900 shares. Atika Capital Limited Company stated it has 20,000 shares. Acadian Asset Mngmt Limited Com accumulated 527 shares. Iowa-based Cambridge Invest Rech Advsr has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). 63,029 are owned by Brown Advisory. Eam Invsts Lc holds 16,903 shares or 0.46% of its portfolio. Invesco Limited has 0.01% invested in Loxo Oncology, Inc. (NASDAQ:LOXO). Principal Financial Group reported 8,383 shares. 182,514 were accumulated by Ubs Asset Mngmt Americas. Bvf Il, California-based fund reported 4,089 shares. Geode Capital Ltd Limited Liability Company stated it has 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Fiera Corporation holds 0.01% or 16,930 shares. Gotham Asset Management Limited stated it has 2,279 shares.

Since June 7, 2018, it had 0 insider purchases, and 22 selling transactions for $303.57 million activity. AISLING CAPITAL III LP also sold $251.20M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares. 2,500 shares were sold by Burstein Jennifer, worth $412,300. On Wednesday, October 3 the insider Bilenker Joshua H. sold $3.30M. The insider Kunkel Lori Anne sold 39,232 shares worth $7.06 million. $8.68 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Flaherty Keith T. on Thursday, June 7. $467,437 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares were sold by Fuhrman Alan.

Loxo Oncology (NASDAQ:LOXO) Rating Reaffirmed

Loxo Oncology (NASDAQ:LOXO) just had their share rating of a ‘Buy’ issued by research analysts at JMP Securities, who now has a $215.0000 target price per share on the $4.30 billion market cap company or a 53.11 % upside potential. This key information was disclosed to clients in analysts report on Tuesday, 27 November.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 8 analysts covering Loxo Oncology (NASDAQ:LOXO), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Loxo Oncology has $235 highest and $165 lowest target. $210.14’s average target is 49.65% above currents $140.42 stock price. Loxo Oncology had 13 analyst reports since June 4, 2018 according to SRatingsIntel. The company was maintained on Wednesday, October 24 by Citigroup. The firm has “Overweight” rating given on Thursday, October 11 by Morgan Stanley. Citigroup maintained the stock with “Buy” rating in Friday, November 16 report. The rating was maintained by JMP Securities with “Market Outperform” on Monday, June 4. The stock has “Overweight” rating by Morgan Stanley on Monday, June 4. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Buy” rating given on Monday, June 4 by Stifel Nicolaus. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) has “Market Perform” rating given on Tuesday, June 5 by IFS Securities. JMP Securities maintained the shares of LOXO in report on Tuesday, November 13 with “Market Outperform” rating. JMP Securities maintained it with “Buy” rating and $21500 target in Tuesday, November 27 report.

The stock increased 0.57% or $0.79 during the last trading session, reaching $140.42. About 353,781 shares traded or 9.87% up from the average. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 119.31% since December 2, 2017 and is uptrending. It has outperformed by 103.69% the S&P500.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $4.30 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: Benzinga.com which released: “Morgan Stanley Upgrades Loxo (NASDAQ:LOXO) On The Potential Of A Targeted Cancer Therapy – Benzinga” on April 16, 2018, also Seekingalpha.com with their article: “Loxo Oncology’s LOXO-292 shows durable effect in type of NSCLC – Seeking Alpha” published on September 25, 2018, Benzinga.com published: “Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings (Nov. 25-Dec. 1) – Benzinga” on November 25, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: Globenewswire.com and their article: “Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress – GlobeNewswire” published on October 09, 2018 as well as Globenewswire.com‘s news article titled: “Loxo Oncology to Announce Second Quarter 2018 Financial Results – GlobeNewswire” with publication date: August 02, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.